english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Ceftazidime + avibactam (Zavicefta°). An option in the case of cephalosporin resistance

FEATURED REVIEW A ceftazidime + avibactam combination (Zavicefta°, Pfizer) has been approved in the European Union for the treatment of various “complicated” infections. In one clinical trial, the combination was as effective as a carbapenem and had an acceptable adverse effect profile.
Full review (2 pages) available for download by subscribers.
1 March 2018

In the March issue of Prescrire International: the annual Prescrire Awards for drugs, packaging and information

FREE DOWNLOAD The three annual Prescrire Awards are granted in total independence by the Prescrire Editorial Staff, based on reviews published over the past year in our French edition.
Full text available for free download.
1 March 2018

Hodgkin disease: two drugs that are not beneficial to patients

In the absence of any proven increase in life expectancy, there is no justification for exposing patients with Hodgkin disease to the many, sometimes severe, adverse effects of nivolumab (Opdivo°) and brentuximab vedotin (Adcetris°).
1 March 2018

Hospitalised children: errors detected by parents and family members

During a child's hospitalisation, family members often detect adverse events and errors which are not noticed or reported by caregivers.
1 March 2018

Early syphilis: screen and treat to prevent transmission

Syphilis is sometimes hard to identify, and so it is important to screen and treat the sexual partners of infected persons to prevent transmission.
1 March 2018

EMA's advice to drug companies: conflicting roles

The European Medicines Agency (EMA) offers "scientific advice" to drug companies to help them compile their marketing authorisation applications, giving rise to suspicions that the agency may be placing pharmaceutical companies' interests over and above patients' health.
1 March 2018

Prescrire's ratings system: new drugs and indications, at a glance

 ABOUT PRESCRIRE  Behind the annual Prescrire Awards, Prescrire's editors work year-round to assess whether or not new drugs and indications represent a therapeutic advance for patients. Ranging from "Bravo" to "Not Acceptable", Prescrire's ratings sum up the result of a unique, collective editorial process.
1 March 2018

Injectable methotrexate and ectopic pregnancy. An alternative to surgery, but patients must be made aware of the risks

FEATURED REVIEW For some women with an ectopic pregnancy, intramuscular injection of methotrexate can be an alternative to surgery. But methotrexate carries the risks of a cytotoxic drug, and is teratogenic: women treated with methotrexate should wait three months before trying to conceive again.
Full review (5 pages) available for download by subscribers.
1 February 2018

In the February issue of Prescrire International: Localised prostate cancer - immediate treatment, or not?

FREE DOWNLOAD In patients with localised prostate cancer, the principal therapeutic options are: monitoring without initial treatment, prostatectomy and radiotherapy. Results of a comparative randomised trial have provided some useful data for providing information to patients.
Full text available for free download.
1 February 2018

Levothyroxine: problems caused by a change in formulation were foreseeable

The specificities of levothyroxine mean that it was foreseeable that a change in formulation would require a careful rebalancing of the treatment for some patients.
1 February 2018

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90